Voyager Therapeutics (VYGR) Operating Income (2016 - 2025)
Historic Operating Income for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to -$30.6 million.
- Voyager Therapeutics' Operating Income fell 12201.74% to -$30.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$140.2 million, marking a year-over-year decrease of 164502.48%. This contributed to the annual value of -$83.3 million for FY2024, which is 16826.02% down from last year.
- Latest data reveals that Voyager Therapeutics reported Operating Income of -$30.6 million as of Q3 2025, which was down 12201.74% from -$36.6 million recorded in Q2 2025.
- Voyager Therapeutics' 5-year Operating Income high stood at $122.9 million for Q1 2023, and its period low was -$38.3 million during Q4 2024.
- Moreover, its 5-year median value for Operating Income was -$24.6 million (2022), whereas its average is -$9.9 million.
- As far as peak fluctuations go, Voyager Therapeutics' Operating Income plummeted by 53077.87% in 2022, and later skyrocketed by 67556.91% in 2023.
- Over the past 5 years, Voyager Therapeutics' Operating Income (Quarter) stood at $5.7 million in 2021, then tumbled by 530.78% to -$24.6 million in 2022, then surged by 320.1% to $54.1 million in 2023, then plummeted by 170.84% to -$38.3 million in 2024, then increased by 20.12% to -$30.6 million in 2025.
- Its Operating Income was -$30.6 million in Q3 2025, compared to -$36.6 million in Q2 2025 and -$34.7 million in Q1 2025.